Skip to main content

Want a detailed portfolio tracker?

DMAA
NASDAQ
$10.70

Drugs Made In America Acquisition Corp (DMAA)

Drugs Made In America Acquisition Corp. (DMAA) is a special purpose acquisition company dedicated to revolutionizing the U.S. pharmaceutical sector through strategic partnerships with innovative healthcare firms. Focused on bolstering domestic drug production and mitigating supply chain risks, DMAA aims to enhance the accessibility and affordability of medications for American consumers. By harnessing advanced technologies and championing local manufacturing efforts, DMAA is poised to significantly influence the landscape of pharmaceutical access in the United States.

This company is also listed under the following tickersDMAAR, DMAAU.

Website: https://dmaacorp.com

Market Cap

$246M

P/E Ratio

41.84

Free Cash Flow Yield

-0.10%

Beta (5Y)

0.01

Price Chart

Valuation
Market Cap$246M
P/E41.84
P/B1.10
Profitability
EBITDA-$539K
EPS$0.26
Financial Health
Debt-to-Equity0%
Free Cash Flow Yield-0.10%
Growth & Risk
Beta (5Y)0.01
Sharpe Ratio0.34